跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

CDS023093

Sigma-Aldrich

尼洛替尼

别名:

4-甲基-3-[[4-(3-吡啶)-2-嘧啶]氨基]-N-[5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基]苯甲酰胺, 4-甲基-N-[3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基]-3-[[4-(3-吡啶)-2-嘧啶]氨基]苯甲酰胺, 4-甲基-N-[3-(4-甲基咪唑-1-基)-5-三氟甲基苯基]-3-[[4-(吡啶-3-基)嘧啶-2-基]氨基]苯甲酰胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H22F3N7O
CAS号:
641571-10-0
分子量:
529.52
MDL编号:
MFCD09833716
UNSPSC代码:
12352200
PubChem化学物质编号:
329796354

描述

AldrichCPR

表单

solid

储存温度

-10 to -25°C

SMILES字符串

CC1=CN(C2=CC(NC(C3=CC=C(C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3)C)=O)=CC(C(F)(F)F)=C2)C=N1

InChI

1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

InChI key

HHZIURLSWUIHRB-UHFFFAOYSA-N

基因信息

human ... ABL1(25)

一般描述

尼洛替尼(Nilotinib)是氨基嘧啶类衍生物，可用作酪氨酸激酶受体的选择性抑制剂。也可作为抗肿瘤和抗冠状病毒药物。

其他说明

请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方需承担确认产品标识和/或纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH′S和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：（A）适销性担保；（B）特定用途适用性担保；或（C）未侵犯第三方知识产权担保。

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H372,H413

危险分类

Aquatic Chronic 4 - STOT RE 1

靶器官

Liver,Kidney,gallbladder

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A Hochhaus et al.
Leukemia, 31(7), 1525-1531 (2017-02-22)
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR
Fabienne Lamballe et al.
Oncotarget, 7(46), 74747-74767 (2016-10-13)
The cytoplasmic tyrosine kinase ABL exerts positive or negative effects in solid tumours according to the cellular context, thus functioning as a "switch modulator". The therapeutic effects of drugs targeting a set of signals encompassing ABL have been explored in
Hans Gelderblom et al.
The Lancet. Oncology, 19(5), 639-648 (2018-03-25)
Pigmented villonodular synovitis (alternatively known as diffuse-type giant cell tumour) is a rare, locally aggressive tumour driven by a specific translocation resulting in the overexpression of colony-stimulating factor 1 (CSF1). CSF1 receptor (CSF1R) inhibitors (ie, tyrosine kinase inhibitors and antibodies)
Main Chemotypes of SARS-CoV-2 Reproduction Inhibitors
Shiryaev VA and Klimochkin Yu N
Russian Journal of Organic chemistry, 57(5), 730-767 (2021)
Qinghui Yang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 42(6), 2182-2193 (2017-08-17)
Cardiotoxicity is a predominant side-effect of nilotinib during chronic myeloid leukemia treatment. The underlying molecular mechanism remains unclear. The role of autophagy and mitochondrial signaling was investigated in nilotinib-treated cardiac H9C2 cells. Cytotoxicity was assessed using Cell Death Detection kit.
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门